Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST4721 in Familial Mediterranean Fever
NCT05448391Phase 2Withdrawn
- Sponsor
- Aristea Therapeutics
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vimnerixin in Familial Mediterranean fever (FMF), sponsored by Aristea Therapeutics. Planned start Sep 2022; status: withdrawn.
02
Drugs
vimnerixin
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT05448391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448391.